Cosmo Pharmaceuticals NV
Company Profile
Business description
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology, and health tech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. The product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, and CB-01-33.
Contact
Sir John Rogerson’s Quay
Riverside II
Dublin2
IRLT: +353 18170370
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
332
Stocks News & Analysis
stocks
Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief
stocks
ASX share ticks all the popular thematic boxes
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,138.50 | 11.40 | 0.12% |
| CAC 40 | 8,313.00 | 45.76 | -0.55% |
| DAX 40 | 25,349.15 | 56.19 | -0.22% |
| Dow JONES (US) | 49,590.20 | 86.13 | 0.17% |
| FTSE 100 | 10,141.63 | 0.93 | 0.01% |
| HKSE | 26,848.47 | 239.99 | 0.90% |
| NASDAQ | 23,733.90 | 62.56 | 0.26% |
| Nikkei 225 | 53,549.16 | 1,609.27 | 3.10% |
| NZX 50 Index | 13,656.05 | 27.24 | -0.20% |
| S&P 500 | 6,977.27 | 10.99 | 0.16% |
| S&P/ASX 200 | 8,808.50 | 17.20 | 0.20% |
| SSE Composite Index | 4,138.76 | 26.53 | -0.64% |